[go: up one dir, main page]

AU2023901365A0 - Administration of oligonucleotides - Google Patents

Administration of oligonucleotides

Info

Publication number
AU2023901365A0
AU2023901365A0 AU2023901365A AU2023901365A AU2023901365A0 AU 2023901365 A0 AU2023901365 A0 AU 2023901365A0 AU 2023901365 A AU2023901365 A AU 2023901365A AU 2023901365 A AU2023901365 A AU 2023901365A AU 2023901365 A0 AU2023901365 A0 AU 2023901365A0
Authority
AU
Australia
Prior art keywords
oligonucleotides
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2023901365A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RAGE Biotech Pty Ltd
Original Assignee
RAGE Biotech Pty Ltd
Filing date
Publication date
Application filed by RAGE Biotech Pty Ltd filed Critical RAGE Biotech Pty Ltd
Publication of AU2023901365A0 publication Critical patent/AU2023901365A0/en
Priority to PCT/AU2023/050961 priority Critical patent/WO2024229505A1/en
Priority to AU2023447308A priority patent/AU2023447308A1/en
Priority to PCT/AU2024/050433 priority patent/WO2024229513A1/en
Abandoned legal-status Critical Current

Links

AU2023901365A 2023-05-05 2023-05-05 Administration of oligonucleotides Abandoned AU2023901365A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/AU2023/050961 WO2024229505A1 (en) 2023-05-05 2023-10-05 Administration of oligonucleotides
AU2023447308A AU2023447308A1 (en) 2023-05-05 2023-10-05 Administration of oligonucleotides
PCT/AU2024/050433 WO2024229513A1 (en) 2023-05-05 2024-05-03 Administration of oligonucleotides

Publications (1)

Publication Number Publication Date
AU2023901365A0 true AU2023901365A0 (en) 2023-05-18

Family

ID=

Similar Documents

Publication Publication Date Title
EP4363444A4 (en) Administration of anti-hpa-1a antibodies
EP4274557A4 (en) Oral administration of ketamine
EP4190310A4 (en) Stable pharmaceutical preparation
AU2023901365A0 (en) Administration of oligonucleotides
EP4114396A4 (en) Methods of administering elagolix
EP4205765A4 (en) Stable pharmaceutical preparation
HK40108562A (en) Oral delivery of oligonucleotides
TWI908143B (en) Use of ribociclib pharmaceutical compositions for the treatment of cancer
HK40122638A (en) Combination drug
AU2023902095A0 (en) Polymer-enabled delivery of pharmaceutical agents
HK40117988A (en) Lipid-based formulations for administration of rna
HK40110997A (en) Pharmaceutical compositions of efruxifermin
EP4370117A4 (en) Pharmaceutical compositions of ozanimod
HK40119846A (en) Oral dosage forms of elraglusib
HK40113753A (en) Pharmaceutical formulation
HK40122488A (en) Pharmaceutical composition comprising centanafadine
HK40117580A (en) Combination formulation of cedazuridine
AU2024901938A0 (en) Medicinal Vapes
AU2024901937A0 (en) Medicinal Vapes
AU2024901936A0 (en) Medicinal vapes
HK40094133A (en) Pharmaceutical composition for the treatment of vitiligo
HK40122546A (en) Combination formulation of cedazuridine
HK40121850A (en) Pharmaceutical composition
HK40103690A (en) Novel combined administration
HK40112311A (en) Pharmaceutical compound